Infliximab Level and Anti‑drug Antibody for IBD
Also known as: IFX, infliximab-dyyb, TNF-alpha inhibitor, ATI, Anti-TNF-alpha blocker antibody
Use
This test measures serum levels of the therapeutic monoclonal antibody infliximab and detects anti‑drug antibodies in individuals with inflammatory bowel disease (IBD). It helps distinguish between pharmacokinetic failures (low drug levels) and immunologic failures (presence of antibodies), guiding dosing decisions and management of primary or secondary loss of response.
Special Instructions
Not provided.
Limitations
Not provided.
Methodology
Immunoassay (ELISA)
Biomarkers
Result Turnaround Time
Not provided.
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
2 mL
Minimum Volume
1 mL
Container
red‑top tube (no gel)
Collection Instructions
Draw blood just before the next infusion (trough level); do not take biotin or vitamin B7 supplements for up to 48 hours prior.
Patient Preparation
Avoid multivitamins or supplements containing biotin (vitamin B7) for up to 48 hours before collection.
Causes for Rejection
Gross hemolysis; use of serum separator tube (SST); grossly icteric sample.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 48 hours |
| Refrigerated | 7 days |
| Frozen | 28 days at –20 °C; 70 days at –70 °C |
Other tests from different labs that may be relevant